All In MedTech

FDA Clearance Tracker · P030016-S035

EVO/EVO+VISIAN Implantable Collamer Lens

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Mar 25, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Mar 25, 2022

Approved

Time to decision

1,240 days

Received Nov 1, 2018. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P030016-S035
Device name
EVO/EVO+VISIAN Implantable Collamer Lens
Applicant location
Monrovia, CA
Received
Nov 1, 2018
Decided
Mar 25, 2022
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P030016

Device type

Device class
Class III
Specialty
Ophthalmology

Every decision under product code MTA

FDA's approval statement

As written in FDA's record.

Approval for the EVO/EVO+ Visian Implantable Collamer Lens. The ICL is indicated for use in patients 21-45 years of age:1. for the correction of myopia with spherical equivalent ranging from -3.0D to less than or equal to-15.0D with less than or equal to 2.5D of astigmatism at the spectacle plane;2. for the reduction of myopia with spherical equivalent ranging from greater than -15.0D to -20.0D with less than or equal to 2.5D of astigmatism at the spectacle plane;3. with an anterior chamber depth (ACD) of 3.00 mm or greater, when measured from the corneal endothelium to the anterior surface of the crystalline lens and a stable refractive history (within 0.5D for 1 year prior to implantation); and4.The ICL is intended for placement in the posterior chamber (ciliary sulcus) of the phakic eye.The EVO TICL is indicated for use in patients 21-45 years of age:1. for the correction of myopic astigmatism with spherical equivalent ranging from -3.0D to less than or equal to -15.0D (in the spectacle plane) with cylinder (spectacle plane) of 1.0D to 4.0D;2. for the reduction of myopic astigmatism with spherical equivalent ranging from greater than -15.0D to -20.0D (in the spectacle plane) with cylinder (spectacle plane)1.0D to 4.0D;3. with an anterior chamber depth (ACD) of 3.00 mm or greater, when measured from the corneal endothelium to the anterior surface of the crystalline lens and a stable refractive history (within 0.5 D for both spherical equivalent and cylinder for 1 year prior to implantation); and4. The TICL is intended for placement in the posterior chamber (ciliary sulcus) of the phakic eye.

Source documents

Other decisions for STAAR Surgical Company

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

2 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.